Anemia Clinical Trial
Official title:
The Effect of Fermented Papaya Preparation on Patients With Chronic Kidney Disease Under Dialysis Receiving Intravenous Iron
Fermented papaya preparation has been reported to bind and neutralize reactive oxygen species as well as iron. Patients undergoing hemodialysis are generally on iron overload status due to their inability to use iron storage adequately. The aim of this study is to evaluate the effect of FPP on the iron status of these patients.
Background and rationale
Patients with chronic kidney disease (CKD) on hemodialysis often suffer from anemia. The
anemia is primarily caused by insufficient production by the failing kidneys of the
erythroid stimulating hormone - erythropoietin (Epo). Oxidative stress may be another reason
for anemia. Oxidative stress in RBCs of these patients may be caused by:
1. Passage of the blood through the plastic tubing during the dialysis procedure. We have
shown oxidative stress in RBCs following passage of blood through similar tubing during
leukopheresis procedure (1). Other groups reported similar effects during hemodialysis.
2. Iron overload - In order to maximize the effect of Epo, the treatment is supplemented
by IV injection of iron. This iron may accumulate and cause iron overload in some
hemodialyzed patients. Under normal conditions, iron is transported in the blood and
enters into cells following binding the plasma protein transferrin. However, when iron
content in the plasma exceeds the binding capacity of transferrin,
non-transferrin-bound iron (NTBI) appears. This iron enters cells via alternative
pathways, and accumulates in the cytosol, where it participates in chemical reactions
(Haber-Weiss, Fenton) that generate reactive oxygen species (ROS). Excess ROS overcomes
the protective cellular anti-oxidant mechanisms and becomes cytotoxic. In the erythroid
system, excess ROS causes accelerated apoptosis (programmed cell death) of precursor
cells in the bone marrow and a short survival of mature RBCs in the circulation,
resulting in chronic anemia. Excess iron and ROS may also damage other cells and lead
to malfunctioning of vital organs, such as the heart and liver (2,3).
FPP has been reported to bind and neutralize (scavenge) ROS (4) as well as free iron
(chelate) (5). Both activities ameliorate the oxidative stress.
Treatment with FPP of various diseases associated with oxidative stress, administered
orally (3 gr. X 3 times a day), have been shown to significantly ameliorate the
symptoms underlying these diseases (6-18). FPP has a long track-record of safe human
consumption (19-20). It has been used for many years as a food-supplement by thousands
of people around the world without any reported side effect.
Research goals
To study the effect of fermented papaya preparation (FPP) on patients with chronic
kidney disease (CKD) under dialysis, receiving intravenous iron.
General Protocol:
This will be a single-arm, open-label, single-center study in 20 patients upon dialysis
receiving IV iron supplementation. All participants will be treated with FPP for 3
months.
Bi-weekly, blood samples will be drawn and the patients will be monitored for
assessment of safety and efficacy.
Detailed Protocol Twenty patients, treated on Hadassah Medical center, Jerusalem, will
be screened and recruited according to clinical criteria.
inclusion criteria: Age 18-70. Any primary kidney disease resulting in ESRD.
Hemodynamically stable status. PTH up to 2-9 times upper normal limits. Patients
receiving ESA may be included.
3. Exclusion criteria:
Any evidence of acute bleeding. Hg level of less than 8 g/dL Patients with known allergy to
Papaya
3. Patients will be treated orally with FPP (3 gr. X 3 times a day) for 3 months.
4. Blood samples will be obtained from all patients prior and during (every 2 weeks)
treatment.
5. Samples will be analyzed for:
Blood chemistry for Potassium, Albumin and Phosphorous (every 2 weeks).
Anemia: Complete blood count, including RBC number and indexes, as well as hemoglobin
content.
Oxidative stress: (once monthly) Reactive oxygen species Reduced glutathione Membrane lipid
peroxidation External phosphatidylserine
Iron overload: (once monthly) Serum ferritin Serum transferin. Labile plasma iron Serum
hepcidin Intracellular labile iron pool
Safety measures:
Adverse events: Frequency, severity, seriousness, time to onset, duration, and relatedness
to study product.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00801931 -
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
|
Phase 1/Phase 2 | |
Completed |
NCT02948283 -
Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
Completed |
NCT03341338 -
Genes-in-Action - Hepcidin Regulation of Iron Supplementation
|
||
Completed |
NCT00060398 -
Epoetin Alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate Cancer
|
Phase 3 | |
Recruiting |
NCT05384691 -
Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Transfusions
|
Phase 2 | |
Not yet recruiting |
NCT06309641 -
Methemoglobinemia Following Intravenous Iron Treatment
|
||
Completed |
NCT02912494 -
A Phase III Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)
|
Phase 3 | |
Completed |
NCT02888171 -
Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency
|
N/A | |
Completed |
NCT02930850 -
Spot-Check Noninvasive Hemoglobin (SpHb) Clinical Validation
|
N/A | |
Completed |
NCT03822884 -
Pharmacokinetic/Pharmacodynamic Study of 3 Subcutaneous Single Dose Epoetin Alfa Formulations in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT02912533 -
A Long-term Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)
|
Phase 3 | |
Completed |
NCT02603250 -
Evaluation of Hemoglobin Measurement Tools for Child Anemia Screening in Rwanda
|
N/A | |
Completed |
NCT02384122 -
Efficacy of Octreotide on Blood and Iron Requirements in Patients With Anemia Due to Angiodysplasias
|
Phase 3 | |
Completed |
NCT02176759 -
Iron Absorption From Rice Fortified With Ferric Pyrophosphate
|
N/A | |
Completed |
NCT02310113 -
Transfusion and Skeletal Muscle Tissue Oxygenation
|
N/A | |
Completed |
NCT01922479 -
Pilot Study of Ferric Carboxymaltose to Treat Iron Deficiency in Asians With Heart Failure
|
Phase 4 | |
Withdrawn |
NCT01934842 -
A Study to Compare Analyte Levels in Blood Collected Using an Investigational Collection Device With a Commercial Predicate
|
N/A | |
Completed |
NCT01693029 -
Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa
|
Phase 3 | |
Terminated |
NCT01535781 -
Study of the Effect of Tranexamic Acid Administered to Patients With Hip Fractures. Can Blood Loss be Reduced?
|
N/A | |
Completed |
NCT01458028 -
Age and Gender Effects on the Pharmacokinetics of BAY85-3934
|
Phase 1 |